HLA-B58


HLA-B (alpha)-β2MG with bound peptide
major histocompatibility complex (human), class I, B58
Alleles	5801, 5802
Structure (See HLA-B)
Shared data
Locus	chr.6 6p21.31

HLA-B58 (B58) is an HLA-B serotype. B58 is a split antigen from the B17 broad antigen, the sister serotype B57.^[1] The serotype identifies the more common HLA-B*58 gene products.^[2] (For terminology help see: HLA-serotype tutorial) B*5801 is associated with allopurinol induced inflammatory necrotic skin disease.

Serotype

B58 and B17 serotype recognition of some more common HLA B*58 alleles^[3]
B*58	B58	B17	Sample
allele	%	%	size (N)
*5801	79	4	2096
*5802	72	3	837

Allele distribution

**HLA B*5801 frequencies**
		freq
ref.	Population	(%)
^[4]	Cameroon Pygmy Baka	15.0
^[4]	India Khandesh Pawra	15.0
^[4]	Cameroon Sawa	11.5
^[4]	Taiwan Hakka	10.9
^[4]	Kenya Nandi	10.0
^[4]	India West Bhils	9.0
^[4]	China South Han	8.9
^[4]	China Inner Mongolia	8.8
^[4]	India North Delhi	8.8
^[4]	Thailand Northeast	8.4
^[4]	Guinea Bissau	7.8
^[4]	Thailand	7.7
^[4]	India Mumbai Marathas	7.4
^[4]	India Andhra Pradesh Golla	7.2
^[4]	Kenya Luo	7.0
^[4]	Senegal Niokholo Mandenka	6.9
^[4]	India New Delhi	6.8
^[4]	Oman	6.8
^[4]	Russia Tuva (2)	6.7
^[4]	South Korea (3)	6.5
^[4]	Italy Sardinia (3)	6.4
^[4]	Burkina Faso Fulani	6.1
^[4]	Taiwan Siraya	5.9
^[4]	India North Hindus	5.8
^[4]	Burkina Faso Mossi	5.7
^[4]	Cameroon Yaounde	5.4
^[4]	Cameroon Bamileke	5.2
^[4]	Singapore Riau Malay	5.0
^[4]	Saudi Arabia Guraiat and Hail	4.6
^[4]	France Corsica	4.5
^[4]	Sudanese	4.5
^[4]	Zimbabwe Harare Shona	4.4
^[4]	Burkina Faso Rimaibe	4.3
^[4]	Iran Baloch	4.0
^[4]	South African Natal Zulu	4.0
^[4]	Tunisia	4.0
^[4]	Uganda Kampala	4.0
^[4]	Cameroon Beti	3.7
^[4]	Tunisia Ghannouch	3.7
^[4]	Taiwan Pazeh	3.6
^[4]	Tunisia Tunis	3.4
^[4]	Italy North (1)	3.3
^[4]	Israel Ashkenazi and Non Ashkenazi Jews	3.2
^[4]	India West Coast Parsis	3.0
^[4]	China North Han	2.9
^[4]	Ivory Coast Akan Adiopodoume	2.3
^[4]	Mali Bandiagara	2.2
^[4]	Mexico Zaptotec Oaxaca	2.2
^[4]	South Africa Natal Tamil	2.0
^[4]	China Yunnan Nu	1.9
^[4]	Bulgaria	1.8
^[4]	China Tibet Autonomous Region Tibetans	1.6
^[4]	France South East	1.6
^[4]	Israel Arab Druse	1.5
^[4]	Czech Republic	1.4
^[4]	Georgia Tbilisi Georgians	1.4
^[4]	Jordan Amman	1.4
^[4]	Morocco Nador Metalsa (berber)	1.4
^[4]	Croatia	1.3
^[4]	Romanian	1.3
^[4]	Spain Eastern Andalusia	1.2
^[4]	Australian Aborigine Cape York Peninsula	1.0
	*B5802**
^[4]	Cameroon Bamileke	14.3
^[4]	Kenya Luo	12.5
^[4]	Cameroon Yaounde	10.9
^[4]	Cameroon Pygmy Baka	10.0
^[4]	Cameroon Beti	9.8
^[4]	Kenya Nandi	8.5
^[4]	South African Natal Zulu	8.5
^[4]	Cameroon Sawa	7.7
^[4]	Zimbabwe Harare Shona	6.4
^[4]	Cape Verde Northwestern Islands	5.6
^[4]	Uganda Kampala	4.4
^[4]	Central Africa Republic Mbenzele Pygmy	4.0
^[4]	Zambia Lusaka	2.3
^[4]	Iran Baloch	1.0
^[4]	Tunisia	1.0

Disease

HLA-B*5801 is involved in allopurinol sensitive drug induced Stevens–Johnson syndrome.^[5]^[6] Allopurinol is a frequent cause of severe cutaneous adverse reactions, including drug-hypersensitivity syndrome, Stevens–Johnson syndrome, and toxic epidermal necrolysis (SJS/TEN).^[7] The association with allopurinol sensitivity in SJS/TEN was extremely strong in Asia, and somewhat less associated in Europeans.^[8]

References

^ Ways JP, Coppin HL, Parham P (1985). "The complete primary structure of HLA-Bw58". J. Biol. Chem. 260 (22): 11924–33. doi:10.1016/S0021-9258(17)38967-6. PMID 2995352.
^ Marsh, S. G.; Albert, E. D.; Bodmer, W. F.; Bontrop, R. E.; Dupont, B.; Erlich, H. A.; Fernández-Viña, M.; Geraghty, D. E.; Holdsworth, R.; Hurley, C. K.; Lau, M.; Lee, K. W.; Mach, B.; Maiers, M.; Mayr, W. R.; Müller, C. R.; Parham, P.; Petersdorf, E. W.; Sasazuki, T.; Strominger, J. L.; Svejgaard, A.; Terasaki, P. I.; Tiercy, J. M.; Trowsdale, J. (2010). "Nomenclature for factors of the HLA system, 2010". Tissue Antigens. 75 (4): 291–455. doi:10.1111/j.1399-0039.2010.01466.x. PMC 2848993. PMID 20356336.
^ derived from IMGT/HLA
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s ^t ^u ^v ^w ^x ^y ^z ^aa ^ab ^ac ^ad ^ae ^af ^ag ^ah ^ai ^aj ^ak ^al ^am ^an ^ao ^ap ^aq ^ar ^as ^at ^au ^av ^aw ^ax ^ay ^az ^ba ^bb ^bc ^bd ^be ^bf ^bg ^bh ^bi ^bj ^bk ^bl ^bm ^bn ^bo ^bp ^bq ^br ^bs ^bt ^bu ^bv ^bw ^bx ^by Middleton D, Menchaca L, Rood H, Komerofsky R (2003). "New allele frequency database". Tissue Antigens. 61 (5): 403–7. doi:10.1034/j.1399-0039.2003.00062.x. PMID 12753660.
^ Chung WH, Hung SI, Chen YT (August 2007). "Human leukocyte antigens and drug hypersensitivity". Curr Opin Allergy Clin Immunol. 7 (4): 317–23. doi:10.1097/ACI.0b013e3282370c5f. PMID 17620823. S2CID 31415054.
^ Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009). "Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population". Pharmacogenet Genomics. 19 (9): 704–9. doi:10.1097/FPC.0b013e328330a3b8. PMID 19696695. S2CID 24941838.
^ Hung SI, Chung WH, Liou LB, et al. (March 2005). "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol". Proc. Natl. Acad. Sci. U.S.A. 102 (11): 4134–9. Bibcode:2005PNAS..102.4134H. doi:10.1073/pnas.0409500102. PMC 554812. PMID 15743917.
^ Lonjou C, Borot N, Sekula P, et al. (February 2008). "A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs". Pharmacogenet. Genomics. 18 (2): 99–107. doi:10.1097/FPC.0b013e3282f3ef9c. PMID 18192896. S2CID 35512622.

[pmid2995352-1] Ways JP, Coppin HL, Parham P (1985). "The complete primary structure of HLA-Bw58". J. Biol. Chem. 260 (22): 11924–33. doi:10.1016/S0021-9258(17)38967-6. PMID 2995352.

[pmid15787720-2] Marsh, S. G.; Albert, E. D.; Bodmer, W. F.; Bontrop, R. E.; Dupont, B.; Erlich, H. A.; Fernández-Viña, M.; Geraghty, D. E.; Holdsworth, R.; Hurley, C. K.; Lau, M.; Lee, K. W.; Mach, B.; Maiers, M.; Mayr, W. R.; Müller, C. R.; Parham, P.; Petersdorf, E. W.; Sasazuki, T.; Strominger, J. L.; Svejgaard, A.; Terasaki, P. I.; Tiercy, J. M.; Trowsdale, J. (2010). "Nomenclature for factors of the HLA system, 2010". Tissue Antigens. 75 (4): 291–455. doi:10.1111/j.1399-0039.2010.01466.x. PMC 2848993. PMID 20356336.

[3] rived from IMGT/HLA

[pmid12753660-4] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p ^q ^r ^s ^t ^u ^v ^w ^x ^y ^z ^aa ^ab ^ac ^ad ^ae ^af ^ag ^ah ^ai ^aj ^ak ^al ^am ^an ^ao ^ap ^aq ^ar ^as ^at ^au ^av ^aw ^ax ^ay ^az ^ba ^bb ^bc ^bd ^be ^bf ^bg ^bh ^bi ^bj ^bk ^bl ^bm ^bn ^bo ^bp ^bq ^br ^bs ^bt ^bu ^bv ^bw ^bx ^by Middleton D, Menchaca L, Rood H, Komerofsky R (2003). "New allele frequency database". Tissue Antigens. 61 (5): 403–7. doi:10.1034/j.1399-0039.2003.00062.x. PMID 12753660.

[pmid17620823-5] Chung WH, Hung SI, Chen YT (August 2007). "Human leukocyte antigens and drug hypersensitivity". Curr Opin Allergy Clin Immunol. 7 (4): 317–23. doi:10.1097/ACI.0b013e3282370c5f. PMID 17620823. S2CID 31415054.

[pmid19696695-6] Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009). "Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population". Pharmacogenet Genomics. 19 (9): 704–9. doi:10.1097/FPC.0b013e328330a3b8. PMID 19696695. S2CID 24941838.

[pmid15743917-7] Hung SI, Chung WH, Liou LB, et al. (March 2005). "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol". Proc. Natl. Acad. Sci. U.S.A. 102 (11): 4134–9. Bibcode:2005PNAS..102.4134H. doi:10.1073/pnas.0409500102. PMC 554812. PMID 15743917.

[pmid18192896-8] Lonjou C, Borot N, Sekula P, et al. (February 2008). "A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs". Pharmacogenet. Genomics. 18 (2): 99–107. doi:10.1097/FPC.0b013e3282f3ef9c. PMID 18192896. S2CID 35512622.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]